A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma

• Published in: Drugs in R&D 2017-09, Vol.17 (3), p.381-388
• Main Authors: Sho, Takuya, Nakanishi, Mitsuru, Morikawa, Kenichi, Ohara, Masatsugu, Kawagishi, Naoki, Izumi, Takaaki, Umemura, Machiko, Ito, Jun, Nakai, Masato, Suda, Goki, Ogawa, Koji, Chuma, Makoto, Meguro, Takashi, Nakamura, Michio, Nagasaka, Atsushi, Horimoto, Hiromasa, Yamamoto, Yoshiya, Sakamoto, Naoya
• Format: Article
• Language: English
• Subjects: Aged; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - pathology; Dose-Response Relationship, Drug; Fluorouracil - administration & dosage; Humans; Inhibitor drugs; Internal Medicine; Liver cancer; Liver Neoplasms - drug therapy; Liver Neoplasms - pathology; Male; Maximum Tolerated Dose; Medicine; Medicine & Public Health; Middle Aged; Molecular Targeted Therapy; Niacinamide - administration & dosage; Niacinamide - analogs & derivatives; Original; Original Research Article; Pharmacology/Toxicology; Pharmacotherapy; Phenylurea Compounds - administration & dosage; Targeted cancer therapy
• ISSN: 1174-5886; 1179-6901
• DOI: 10.1007/s40268-017-0187-7

Background and aims Sorafenib is the first molecular targeted drug approved for the treatment of advanced hepatocellular carcinoma (HCC) and is a potent small molecule inhibitor of multiple kinases. Combination therapy with sorafenib and other cytotoxic agents for HCC may result in additive anticancer activity. The purpose of this phase I study was to investigate the safety and tolerability of combination therapy with sorafenib and 5-fluorouracil (5-FU) and to determine the optimum dose of 5-FU for a phase II trial. Methods This phase I study used a conventional 3 + 3 dose-escalation design. The primary endpoint was to determine the maximum tolerated dose (MTD) of 5-FU in combination with sorafenib and to determine the recommended dosage (RD) for phase II. The secondary endpoints evaluated were toxicity and the tumor response rate. All patients received 800 mg of sorafenib daily and three different dosages of 5-FU (250, 350, and 450 mg/m 2 /day) for 20 days by intravenous infusion in 1 month as one cycle. Results Twelve patients with advanced HCC were evaluated. The MTD of 5-FU in combination with sorafenib was 450 mg/m 2 /day, and 350 mg/m 2 /day was selected as the RD for a phase II study. Thrombocytopenia, stomatitis, and hand-foot skin reaction were observed as grade 3 adverse events. Nine patients achieved stable disease (75%), and three patients (25%) were judged to have progressive disease. The disease control rate was 75%. Conclusions Combination therapy with sorafenib and 5-FU appears to be well tolerated and may have the potential to be an option for advanced HCC.